Gilead Sciences (GILD +0.4%) agrees to acquire YM BioSciences (YMI) for $510M, with the...


Gilead Sciences (GILD +0.4%) agrees to acquire YM BioSciences (YMI) for $510M, with the $2.95/share offer representing an 81% premium to the latter's close of $1.63 yesterday. With the deal, Gilead will gain access to YM's blood and immune cell disorder drugs. Its lead drug candidate is CYT387 for treating myelofibrosis, a progressive, chronic bone marrow disease. YM shares sky 78%. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs